Equities

Puma Biotechnology Inc

PBYI:NSQ

Puma Biotechnology Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.02
  • Today's Change-0.19 / -5.92%
  • Shares traded67.97k
  • 1 Year change-20.53%
  • Beta1.0479
Data delayed at least 15 minutes, as of Nov 13 2024 15:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.

  • Revenue in USD (TTM)243.57m
  • Net income in USD23.24m
  • Incorporated2010
  • Employees185.00
  • Location
    Puma Biotechnology Inc10880 Wilshire Blvd., Suite 2150LOS ANGELES 90024United StatesUSA
  • Phone+1 (424) 248-6500
  • Fax+1 (424) 248-6501
  • Websitehttps://www.pumabiotechnology.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vigil Neuroscience Inc0.00-82.60m147.17m66.00--1.61-----2.07-2.070.002.230.00----0.00-56.88---66.15--------------0.00-------20.98------
PepGen Inc0.00-87.23m147.98m64.00--1.08-----2.98-2.980.004.220.00----0.00-52.16---58.79--------------0.00-------13.78------
Outlook Therapeutics Inc0.00-94.05m148.32m24.00---------8.12-8.120.00-3.570.00----0.00-205.48-214.69---1,843.48-------3,043.92---26.89--------10.70------
Ventyx Biosciences Inc0.00-152.52m148.41m75.00--0.5324-----2.37-2.370.003.940.00----0.00-48.98---52.21--------------0.00-------77.97------
Repare Therapeutics Inc66.52m-84.05m148.57m179.00--0.8492--2.23-2.00-2.001.564.120.270--3.95371,642.50-34.11-23.40-40.73-26.37-----126.34-162.76----0.00---61.21---222.91--27.16--
CytoDyn Inc0.00-20.53m152.48m9.00---------0.0241-0.02410.00-0.06990.00----0.00-94.20-259.15-----------232,918.20--1.36--------35.70------
Context Therapeutics Inc0.00-18.57m153.75m5.00--1.52-----1.06-1.060.001.350.00----0.00-28.46---29.68--------------0.00-------61.53------
Checkpoint Therapeutics Inc78.00k-42.47m155.31m23.00------1,991.17-1.50-1.500.0027-0.3720.0111--2.173,391.30-606.33-142.43---342.79-----54,444.87-6,554.97---------46.35-50.6117.21------
Puma Biotechnology Inc243.57m23.24m157.44m185.006.762.224.520.64640.4750.4755.031.451.1517.915.831,316,589.0010.95-12.2118.85-20.5369.2978.789.54-11.791.403.610.5234--3.34-1.251,079,450.00--83.41--
Achieve Life Sciences Inc0.00-32.94m159.69m22.00--5.10-----1.13-1.130.000.91240.00----0.00-91.19-86.31-107.21-119.59-----------22.540.2384------29.60---14.51--
Cardiff Oncology Inc689.00k-43.01m160.56m31.00--3.10--233.03-0.9493-0.94930.01521.010.0091--1.6922,225.81-56.80-31.24-66.22-33.56-----6,238.17-7,819.23----0.00--26.425.22-7.07--157.91--
Acumen Pharmaceuticals Inc0.00-64.86m160.71m51.00--0.6588-----1.11-1.110.004.060.00----0.00-27.82---29.32--------------0.1075-------22.20------
Skye Bioscience Inc0.00-42.29m163.52m11.00--2.08-----3.91-3.910.002.590.00----0.00-94.50-232.67-129.40-------------323.100.0626-------93.23--23.38--
Adverum Biotechnologies Inc1.00m-94.11m164.13m121.00--1.14--164.13-6.03-6.030.05856.930.0046----8,264.46-43.66-36.39-50.24-39.04-----9,411.10-5,279.60----0.00----17.4324.18---0.0247--
Vaxart Inc13.93m-75.66m164.26m109.00--2.05--11.79-0.4707-0.47070.08610.35180.1178--5.80127,779.80-64.01-49.60-73.18-54.86-----543.21-1,398.00---226.730.0507--6,796.2612.1523.47--21.49--
Data as of Nov 13 2024. Currency figures normalised to Puma Biotechnology Inc's reporting currency: US Dollar USD

Institutional shareholders

38.69%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 20243.55m7.24%
Millennium Management LLCas of 30 Jun 20243.16m6.45%
BlackRock Fund Advisorsas of 30 Jun 20242.80m5.71%
Acadian Asset Management LLCas of 30 Jun 20241.95m3.98%
Renaissance Technologies LLCas of 30 Jun 20241.75m3.57%
Great Point Partners LLCas of 30 Jun 20241.49m3.03%
Eversept Partners LPas of 30 Jun 20241.33m2.71%
Athyrium Capital Management LPas of 30 Jun 20241.26m2.56%
Geode Capital Management LLCas of 30 Jun 2024950.15k1.94%
American Century Investment Management, Inc.as of 30 Jun 2024738.90k1.51%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.